ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe
27. November 2024 04:30 ET
|
Advanz Pharma
ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The conditional marketing authorisation...
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)
03. September 2024 04:00 ET
|
Advanz Pharma
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...
UDCA Market Insights and Forecast to 2032: Mechanism of Action, Regulatory Milestones, and Growth Forecast for PBC Treatment
12. März 2024 12:26 ET
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "UDCA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report encapsulates crucial...
Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom
11. März 2024 05:09 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Primary Biliary Cholangitis Therapeutics Market" report has been added to ResearchAndMarkets.com's offering. The global primary biliary...
OCALIVA for Primary Biliary Cirrhosis (PBC) Drug Landscape Report 2024: Market Size, Analysis and Forecasts, 2019-2023 and 2024-2032 - Focus on United States, Germany, France, Italy, Spain and UK
01. März 2024 09:27 ET
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "OCALIVA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This research report provides...
Challenges in Non-Alcoholic Steatohepatitis (NASH) Diagnosis and Lack of Definitive Methods Hamper Market Growth Despite Rising Awareness
10. November 2023 08:23 ET
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential...
Promising PBC Therapeutics Advancements Fuel Market Growth Opportunities for Key Players
04. Oktober 2023 10:58 ET
|
Research and Markets
Dublin, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Therapeutics Market By Drug type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032"...
ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Intercept Pharmaceuticals to Alfasigma
26. September 2023 11:27 ET
|
Wohl & Fruchter LLP
MONSEY, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT)...
$5.5+ Billion Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel - Global Forecasts to 2028
08. September 2023 09:53 ET
|
Research and Markets
Dublin, Sept. 08, 2023 (GLOBE NEWSWIRE) -- The "Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2023-2028" report has been added to ...
NASH Treatment & Therapeutics Market Report 2023 - Urbanization and Sedentary Lifestyles Fueling the NASH Epidemic
22. August 2023 05:33 ET
|
Research and Markets
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "NASH Treatment & Therapeutics Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. The report presents a...